Safety and Efficacy of the Noncessation Method of Antithrombotic Agents after Emergency Endoscopic Hemostasis in Patients with Nonvariceal Upper Gastrointestinal Bleeding: A Multicenter Pilot Study

Table 5

Comparison of treatment outcome between groups A and B after propensity score matching.

	Group A	Group B	value
Number of patients (N)	40	40
Cessation period (day)^a	0 (0–0)	6.5 (3.3–10)	<0.001
Hemoglobin on admission (g/dL)	8.1 ± 2.6	7.6 ± 1.7	0.31
Transfusion volume (U)	3.0 ± 2.6	2.6 ± 2.9	0.58
Endoscopic hemostasis	40 (100%)	40 (100%)	1.00
Main modality of hemostasis			<0.001
Soft coagulation	39 (97.5%)	24 (60.0%)
Hemoclips	1 (2.5%)	14 (35.0%)
Absolute ethanol injection	0 (0%)	2 (5%)
Operator of hemostasis			0.82
Trainees	24 (60.0%)	26 (65.0%)
Specialists	16 (40.0%)	14 (35.0%)
Hospitalization periods (day)	8.6 ± 5.2	14.4 ± 7.1	<0.001

^aMedian (interquartile range). Group A: patients taking antithrombotic agents who underwent emergency endoscopic hemostasis for nonvariceal upper gastrointestinal bleeding and resumed antithrombotic medication without a cessation period; group B: patients taking antithrombotic agents who underwent emergency endoscopic hemostasis for nonvariceal upper gastrointestinal bleeding for whom antithrombotic medication was transiently discontinued.